Aron R. English sold $86k of LFCR
owner at LIFECORE BIOMEDICAL, INC. \DE\. 12,334 shares at an average of $7.00, traded May 13, 2025, filed May 16, 2025.
Score components
- +12Role10% owner
- +9Trade size$86k at market
- 0Share of holdings soldSold 0.7% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-073196, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 13, 2025 | SOpen-market sale Common Stockindirect: By: 22NW Fund, LP | -12,334 | $7.00 | $86k | 1,650,240 | May 16, 2025 |
Related signals
Other insiders at LIFECORE BIOMEDICAL, INC. \DE\ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $9.1M 1,386,060 shares | -84% | |
| 27Weak | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $362k 51,496 shares | -3% | |
| 26Weak | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $290k 41,091 shares | -2% | |
| 35Weak | LFCRbuy LIFECORE BIOMEDICAL, INC. \DE\ | Paul Josephs Chief Executive Officer | $98k 17,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.